These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7682753)

  • 1. Fibrinolytic components in fetal membranes and amniotic fluid.
    Watanabe T; Araki M; Mimuro J; Tamada T; Sakata Y
    Am J Obstet Gynecol; 1993 Apr; 168(4):1283-9. PubMed ID: 7682753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation.
    Gilabert J; Estellés A; Ayuso MJ; España F; Chirivella M; Grancha S; Micó JM; Aznar J
    Gynecol Obstet Invest; 1994; 38(3):157-62. PubMed ID: 8001867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
    Estellés A; Gilabert J; Andrés C; España F; Aznar J
    Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator activity and urokinase inhibitor activity in human amniotic fluid and fetal membranes.
    Milwidsky A; Finci Z; Mayer M
    Clin Biochem; 1988 Oct; 21(5):301-6. PubMed ID: 3233741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of delivery on plasminogen activator inhibitor activity.
    Koelbl H; Kirchheimer J; Tatra G
    J Perinat Med; 1989; 17(2):107-11. PubMed ID: 2681664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen, alpha(2)-antiplasmin and complexes of plasmin-alpha(2)-antiplasmin (PAP) in amniotic fluid and blood plasma of parturient women.
    Uszynski M; Klyszejko A; Zekanowska E
    Eur J Obstet Gynecol Reprod Biol; 2000 Dec; 93(2):167-71. PubMed ID: 11074138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolytic activity in amniotic fluid during late pregnancy.
    Pschera H; Kjaeldgaard A; Larsson B
    Acta Obstet Gynecol Scand; 1986; 65(5):417-20. PubMed ID: 3776484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture.
    Andolf E; Casslén B; Jörgensen C; Buchhave P; Lecander I
    Obstet Gynecol; 1995 Oct; 86(4 Pt 1):529-35. PubMed ID: 7675374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation and fibrinolysis in amniotic fluid: physiology and observations on amniotic fluid embolism, preterm fetal membrane rupture, and pre-eclampsia.
    Uszyński M; Uszyński W
    Semin Thromb Hemost; 2011 Mar; 37(2):165-74. PubMed ID: 21370219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human fetal membranes: a target tissue for relaxin.
    Koay ES; Bryant-Greenwood GD; Yamamoto SY; Greenwood FC
    J Clin Endocrinol Metab; 1986 Mar; 62(3):513-21. PubMed ID: 3003143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic balance and lupus anticoagulant in patients with repeated spontaneous fetal loss.
    Ferro D; Violi F; Quintarelli C; Sebastianelli A; D'Amelio R; Zichella L; Balsano F
    BMJ; 1992 Aug; 305(6852):504-5. PubMed ID: 1392996
    [No Abstract]   [Full Text] [Related]  

  • 12. [Determination of the enzyme activity of the fibrinolytic system using fibrinogen conjugated with peroxidase].
    Liaginskiĭ AV; AfanasenkoGA ; Gudkova EV
    Lab Delo; 1991; (11):27-31. PubMed ID: 1722843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma.
    Lecander I; Astedt B
    Br J Haematol; 1986 Feb; 62(2):221-8. PubMed ID: 3484964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activators in synovial fluid and plasma from patients with arthritis.
    Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
    Ann Rheum Dis; 1992 Aug; 51(8):965-8. PubMed ID: 1417121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intrauterine defensive mechanism of amniotic fluid and fetal membranes].
    Kanayama N
    Nihon Sanka Fujinka Gakkai Zasshi; 1994 Aug; 46(8):673-85. PubMed ID: 8089604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
    Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
    J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease.
    Estellés A; Grancha S; Gilabert J; Thinnes T; Chirivella M; España F; Aznar J; Loskutoff DJ
    Am J Pathol; 1996 Oct; 149(4):1229-39. PubMed ID: 8863672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues; Measurements and clinical implications.
    Uszyński M; Perlik M; Uszyński W; Zekanowska E
    Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):54-8. PubMed ID: 15099871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial cell-derived neutrophil-activating peptide-78 is present in fetal membranes and amniotic fluid at increased concentrations with intra-amniotic infection and preterm delivery.
    Keelan JA; Yang J; Romero RJ; Chaiworapongsa T; Marvin KW; Sato TA; Mitchell MD
    Biol Reprod; 2004 Jan; 70(1):253-9. PubMed ID: 13679321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma.
    Schönermark MP; Issing PR; Erbrich BK; Lenarz T
    Ann Otol Rhinol Laryngol; 1999 Mar; 108(3):245-52. PubMed ID: 10086616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.